AIM ImmunoTech enters into clinical research agreement with AstraZeneca and Erasmus MC for pancreatic cancer study

AIM ImmunoTech Inc.

Collaboration to evaluate Ampligen (rintatolimod) combined with AstraZeneca's durvalumab in metastatic pancreatic ductal adenocarcinoma.
Erasmus MC will sponsor and conduct a phase II, non-randomized, open-label, single-arm study (DURIPANC Study).
AIM supplies rintatolimod; AstraZeneca supplies durvalumab; AIM retains all intellectual property rights.
Erasmus owns study data but grants AIM unrestricted use; AIM owns inventions related to rintatolimod.
Agreement terminable on completion, material breach, insolvency, or ethics committee rejection.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into external sponsored collaborative clinical research agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV (effective 2023-01-13).

Action: entry
Agreement: collaboration
Counterparty: Erasmus University Medical Center Rotterdam and AstraZeneca BV
Effective: 2023-01-13

Exact text from the filing

On January 13, 2023, we entered into an external sponsored collaborative clinical research agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV, pursuant to which Erasmus is sponsoring and planning to perform an investigator-initiated clinical study, entitled Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect (the “Study”) in which it will use both study drugs provided by AstraZeneca and us.

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-001536

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.